Melanoma
Immunocore Holdings has announced that the European Commission has approved KIMMTRAK® (tebentafusp) for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatcv uveal melanoma (mUM).
Kimmtrack is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function.
![[column] Toekomst tijdschriften glanst als nooit tevoren](https://www.pharmamarketeer.nl/wp-content/uploads/2024/12/happy-couple-in-t-shirts-reading-newspaper-while-h-2024-11-10-00-13-23-utc-1-80x60.jpg)
![[column] MarketingAffairs 17: Marketing als oplossing](https://www.pharmamarketeer.nl/wp-content/uploads/2024/12/asian-seo-manager-writing-on-glass-with-illustrati-2024-11-17-23-11-51-utc-1-80x60.jpg)
